Methotrexate used as a steroid-sparing agent in non-renal chronic Henoch-Schönlein purpura

P Rettig; R Q Cron

Methotrexate used as a steroid-sparing agent in non-renal chronic Henoch-Schönlein purpura

Clin Exp Rheumatol. 2003 Nov-Dec;21(6):767-9.

Authors

P Rettig¹, R Q Cron

Affiliation

¹ Children's Hospital of Philadelphia, Division of Rheumatology, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

PMID: 14740458

Abstract

Henoch-Schönlein purpura (HSP) is the most common form of systemic vasculitis in childhood and a small percentage of children develop a chronic form of the disease that often requires prolonged corticosteroid therapy. A detailed case description of a child with non-renal chronic HSP treated with methotrexate to allow for tapering of corticosteroids is presented. This represents the first report of methotrexate use in the treatment of chronic HSP.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Adrenal Cortex Hormones / adverse effects*
Adrenal Cortex Hormones / therapeutic use
Child
Chronic Disease
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Humans
IgA Vasculitis / diagnosis
IgA Vasculitis / drug therapy*
Injections, Subcutaneous
Long-Term Care
Male
Methotrexate / administration & dosage*
Risk Assessment
Severity of Illness Index
Treatment Outcome

Substances

Adrenal Cortex Hormones
Methotrexate